These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38258519)

  • 1. Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia.
    Chen Z; Wang Q; Yan YY; Jin D; Wang Y; Zhang XX; Liu XH
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305852. PubMed ID: 38258519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia.
    Zhang XX; Yan YY; Ma X; Xiao Y; Lei CC; Wang YM; Liu C; Wang Q; Zhang XT; Cheng WD; Liu XH
    Eur J Med Chem; 2023 May; 251():115214. PubMed ID: 36889252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
    Lee JC; Liu S; Wang Y; Liang Y; Jablons DM
    Oncotarget; 2022 Nov; 13():1217-1236. PubMed ID: 36342456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the Novel 1
    Zhang XX; Xiao Y; Yan YY; Wang YM; Jiang H; Wu L; Shi JB; Liu XH
    J Med Chem; 2022 Sep; 65(18):12095-12123. PubMed ID: 36068975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
    Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
    Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Potent and Selective FLT3 Inhibitor (
    Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
    J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors.
    Hsu JY; Hsu KC; Sun C; Chou CH; Lin TE; Sung TY; Tseng HJ; Yen SC; Yang CR; Huang WJ
    Biomed Pharmacother; 2023 Mar; 159():114258. PubMed ID: 36708700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
    Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
    Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
    Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
    Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
    Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
    Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
    J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
    Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
    Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.
    Wang Y; Zhi Y; Jin Q; Lu S; Lin G; Yuan H; Yang T; Wang Z; Yao C; Ling J; Guo H; Li T; Jin J; Li B; Zhang L; Chen Y; Lu T
    J Med Chem; 2018 Feb; 61(4):1499-1518. PubMed ID: 29357250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
    Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of a novel pyrrolo[2,3-b]pyridine as a selective CDK8 inhibitor offers a new approach against psoriasis.
    Yan YY; Wang YM; Shen JH; Jian YJ; Lei CC; Wang Q; Liu C; Zhang XX; Liu XH
    Biomed Pharmacother; 2024 Jun; 175():116705. PubMed ID: 38713949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
    Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
    Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease
    Yan Y; Xing C; Xiao Y; Shen X; Zhang Z; He C; Shi JB; Liu M; Liu X
    J Med Chem; 2022 May; 65(10):7334-7362. PubMed ID: 35536548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
    Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
    Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.